Yang N - Search Results

1

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.

Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. Among authors: yang n, yang h. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580297 Free PMC article. Clinical Trial.

2

PIDD Mediates Radiation-Induced Microglia Activation.

Yang N, Gao X, Qu X, Zhang R, Tong F, Cai Q, Dong J, Hu Y, Wu G, Dong X. Yang N, et al. Radiat Res. 2016 Oct;186(4):345-359. doi: 10.1667/RR14374.1. Epub 2016 Sep 19. Radiat Res. 2016. PMID: 27643878

3

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.

Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, Liu Y, Wang Y, Zhou C. Yang Z, et al. Among authors: yang n. Clin Cancer Res. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310. Epub 2018 Mar 5. Clin Cancer Res. 2018. PMID: 29506987

4

EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.

Zeng L, Zhang Y, Yang N. Zeng L, et al. Among authors: yang n. J Thorac Oncol. 2018 Jun;13(6):e93-e95. doi: 10.1016/j.jtho.2018.01.006. J Thorac Oncol. 2018. PMID: 29793651 Free article. No abstract available.

5

Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation.

Liao D, Yao D, Liu N, Cao L, Xiang D, Yang N, Zhang Y, Jiang W, Zhou C. Liao D, et al. Among authors: yang n. Cancer Chemother Pharmacol. 2018 Sep;82(3):551-559. doi: 10.1007/s00280-018-3642-4. Epub 2018 Jul 23. Cancer Chemother Pharmacol. 2018. PMID: 30039303

6

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Wu YL, Wang CL, Liao ML, Guan ZZ, Gao CY, Lu S, Zhao MF, Wang J, Liu XQ, Yang JJ, Liang J, Mao WM, Han BH, Zhang XC, Song Y, Feng JF, Ma SL, Wu G, Zhou CC, Chen KN, Cheng Y, He Y, Chen C, Wang Q, Lin JZ, Zhu B, Liu YP, Hu Y, Qiao GB, Zhou Q, Song QB, Wu N, Wu L, Huang C, Fu XL, Xiong JP, Hu J, Hu CP, Chang JH, Zhao Q, Zhao J, Zhou PH, Ma ZY, Chen Y, Zhang HL, Yang F, Wang JJ, Pan YY, Yang XN, Fan Y, Liu Z, Fan W, Yang N, Guan YF, Sun H, Zhong WZ. Wu YL, et al. Among authors: yang xn, yang f, yang jj, yang n. Transl Lung Cancer Res. 2018 Jun;7(3):428-436. doi: 10.21037/tlcr.2018.04.15. Transl Lung Cancer Res. 2018. PMID: 30050780 Free PMC article. Review.

7

Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.

Wang Z, Zhang H, Zhou C, Long X, Guan R, Yang N, Zhang Y. Wang Z, et al. Among authors: yang n. Cancer Med. 2019 Apr;8(4):1434-1441. doi: 10.1002/cam4.2014. Epub 2019 Feb 14. Cancer Med. 2019. PMID: 30762300 Free PMC article.

8

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient.

Hu Y, Xiao L, Yang N, Zhang Y. Hu Y, et al. Among authors: yang n. Thorac Cancer. 2019 May;10(5):1252-1255. doi: 10.1111/1759-7714.13015. Epub 2019 Feb 20. Thorac Cancer. 2019. PMID: 30788907 Free PMC article.

9

The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer.

Yang H, Liu L, Zhou C, Xiong Y, Hu Y, Yang N, Qu J. Yang H, et al. Among authors: yang n. Medicine (Baltimore). 2019 Mar;98(12):e14893. doi: 10.1097/MD.0000000000014893. Medicine (Baltimore). 2019. PMID: 30896637 Free PMC article.

10

Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.

Zeng L, Xia C, Zhang Y, Yang N. Zeng L, et al. Among authors: yang n. J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026. J Thorac Oncol. 2019. PMID: 30922580 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,485 results

Search Page